BERLIN (AP) — German pharmaceutical company Merck KgaA says a late stage trial of a new lung cancer drug has failed to meet expectations.
The company, based in Darmstadt, says the drug Stimuvax did not improve the overall survival of patients in the phase III study.
Merck shares fell 3.1 percent to €98.20 ($129.41) after the announcement early Wednesday.
The company is a separate entity from Merck & Co., which is based in the U.S.
Quotes of the day
- What Is Your U.S. Income Percentile Ranking?
Doug Giles - Here’s Why Islam Wants Our Heads -- In THEIR Own Words
Ted Cruz Teaches Us How To Deal With The Media | RedState
Concealed Carry: What To Do When Stopped By The Police - Bearing Arms - Concealed Cary, Video
Climate protesters trash memorial for terror victims in Paris [photos]
Importing Terrorism and Other American Values | Human Events